In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan

Nai Cheng Cheng, Po Ren Hsueh, Yung Ching Liu, Jainn Ming Shyr, Wen Kuei Huang, Lee Jene Teng, Cheng Yi Liu

研究成果: 雜誌貢獻文章同行評審

27 引文 斯高帕斯(Scopus)

摘要

This study evaluated the in vitro activities of tigecycline, ertapenem, isepamicin, and other comparators against 861 bacterial isolates recovered from patients treated in three major teaching hospitals in 2003. MICs to antimicrobial agents were determined by the agar dilution method. High rates of oxacillin resistance (58%) in Staphylococcus aureus (60 isolates), and vancomycin resistance (21%) and quinupristin-dalfopristin nonsusceptibility (39%) in Enterococcus faecium (34 isolates) were found. Carbapenems had excellent in vitro activities (≥98% susceptibility) against the 419 isolates of Enterobacteriaceae, with the MIC 50 and MIC 90 of imipenem, meropenem, and ertapenem being 0.25 and 4 mg/L, 0.03 and 0.12 mg/L, and 0.03 and 0.5 mg/L, respectively. For, Pseudomonas aeruginosa (74 isolates) and Burkholderia cepacia (21 isolates), meropenem (MIC 90, 0.25, 2, and 4 mg/L, respectively) had better in vitro activities than imipenem (MIC 90, 8, 4, and 32 mg/L, respectively) and ertapenem (MIC 90, 0.5, > 32, and 32 mg/L, respectively). Isepamicin had a similar activity with amikacin against all Enterobacteriaceae, Pseudomonas aeruginosa, B. cepacia, and Acinetobacter baumannii, except for C. freundii isolates in which isepamicin had an eight-fold activity better than amikacin. Tigecycline had excellent in vitro activities against all isolates tested (MIC 90, ≤1 mg/L) including 14 pandrug-resistant A. baumannii isolates (MICs, 1-4 mg/L), except for Proteus mirabilis (59 isolates; MIC 90, 8 mg/L), Bacteroides fragilis (60 isolates; MIC 90, 8 mg/L), P. aeruginosa (MIC 90,16 mg/L), and B. cepacia (21 isolates; MIC 90, 16 mg/L). Tigecycline, carbapenems, and isepamicin exhibited better or comparable in vitro activities against a wide spectrum of commonly encountered bacteria than other comparator antimicrobials and may represent therapeutic options for infections due to multidrug-resistant pathogens.

原文英語
頁(從 - 到)330-341
頁數12
期刊Microbial Drug Resistance
11
發行號4
DOIs
出版狀態已發佈 - 十二月 2005
對外發佈Yes

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology
  • Immunology
  • Microbiology

指紋 深入研究「In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan」主題。共同形成了獨特的指紋。

引用此